New drug BM230 enters first human trials for advanced cancers

NCT ID NCT06644300

Recruiting now Disease control Sponsor: Suzhou Biomissile Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This early-phase study tests a new drug called BM230 in people with advanced solid tumors that are linked to HER2. The goal is to find a safe dose and check for side effects. About 123 participants will take part, first in a dose-finding stage, then in a stage that looks more closely at how well the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan Unversity Zhongshan Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Icon Cancer Centre - South Brisbane
RECRUITING

Brisbane, Queensland, 4101, Australia
Monash Health - Monash Medical Centre
RECRUITING

Monash, Victoria, Australia
Southern Oncology Clinical Research Unit
RECRUITING

Adelaide, South Australia, Australia
The first Affiliated Hospital of Bengbu Medical University
RECRUITING

Bengbu, Anhui, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, China

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR